May & Baker

May & Baker. It was a prominent British pharmaceutical and chemical company, founded in the 19th century and renowned for its significant contributions to medicinal chemistry. The firm played a crucial role in developing early antibacterial drugs and became a major part of the Rhône-Poulenc group. Its legacy endures through its pioneering research and the continued production of its key drug discoveries.

History

The company was established in 1834 in London by chemists John May and William Baker, initially operating as a partnership focused on fine chemicals. In 1927, it was incorporated as May & Baker Ltd., marking a shift towards intensive research and manufacturing. A pivotal moment came in 1929 when the French chemical conglomerate Société Chimique des Usines du Rhône, later Rhône-Poulenc, acquired a controlling interest, providing substantial capital for expansion. During the Second World War, its researchers, under the direction of scientists like A.J. Ewins, made critical advancements in sulfonamide drugs for the British Army. The post-war era saw major growth, with the opening of a large manufacturing site at Dagenham and later significant research facilities at Harlow.

Products and operations

The company's research yielded several landmark pharmaceuticals. Its most famous early success was the development of Sulfapyridine (M&B 693), the first effective drug against pneumonia, which was used extensively during the Second World War and famously treated Winston Churchill. Other major products included the antileprosy drug Dapsone and the antiemetic Stemetil. Beyond human medicine, it was a leader in veterinary pharmaceuticals and agrochemicals, producing products for ICI. Its manufacturing operations were centered at sites in Dagenham, Harlow, and Kingston upon Hull, with a strong export business across the British Empire and Commonwealth of Nations.

Corporate structure and ownership

Following the 1929 acquisition, the company operated as the principal UK subsidiary of the Rhône-Poulenc group, though it retained considerable operational independence for decades. In 1962, it was fully integrated as the UK branch of Rhône-Poulenc Ltd.. This structure facilitated technology transfer between the British firm and its French parent, as well as with other group companies like Roussel-Uclaf. The brand name was gradually phased out in the 1990s following the merger of Rhône-Poulenc with Hoechst AG to form Aventis. Subsequent mergers led to the absorption of its former operations into what is now Sanofi.

Legacy and impact

The company's legacy is firmly rooted in its historic breakthroughs in chemotherapy. The development of Sulfapyridine marked a turning point in the treatment of bacterial infections, saving countless lives during the war and paving the way for modern antibiotics. Its work on Dapsone provided the first effective systemic treatment for leprosy, transforming patient outcomes globally. The long-standing May & Baker brand was highly respected within the National Health Service and the wider British pharmaceutical industry. While the corporate entity is gone, its foundational research continues to impact global health, and its story remains a significant chapter in the history of industrial research in the United Kingdom.

Category:Pharmaceutical companies of the United Kingdom Category:Companies established in 1834 Category:Manufacturing companies based in London